In Brief: Genentech v. Novo Nordisk and BTG
Executive Summary
Genentech v. Novo Nordisk and BTG: Human growth hormone patent infringement complaint dismissed with prejudice against Genentech by the International Trade Commission Jan. 17 after it agrees with the ALJ's Nov. 30 recommendation ("The Pink Sheet" Dec. 5, 1994, T&G-3). Both Novo and Biotechnology General have filed for declaratory judgments that their products do not infringe Genentech patents and those patents are unenforceable and invalid...